AUREALIS PHARMA
Aurealis Pharma is a biopharmaceutical company aiming at developing ground-breaking medicines for the treatment of cancer and chronic wounds. They are dedicated in the R&D of gene and cell based therapies, as well as the development of new active molecules by computational modeling of nature derived compounds. Their key strategy is to perform outstanding interdisciplinary R&D and to implement these into new business models. They are actively seeking for collaborations with pharmaceutical companies, academic research institutions and pre-clinical CROs.
AUREALIS PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2010-04-01
Address:
Kuopio, Eastern Finland, Finland
Country:
Finland
Website Url:
http://www.aurealispharma.com
Total Employee:
1+
Status:
Active
Contact:
+358458433550
Total Funding:
13.4 M CHF
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Fastly Hosted Fastly Load Balancer Hover
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Fosun Pharma
Fosun Pharma is a pharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Jamjoom Pharma
Jamjoom Pharma is pharmaceutical company
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Swedish Orphan Biovitrum
International Pharmaceutical Manufacture
Current Advisors List
Current Employees Featured
Founder
Investors List
Finnvera Venture Capital
Finnvera Venture Capital investment in Series B - Aurealis Pharma
Business Finland
Business Finland investment in Series B - Aurealis Pharma
Finnvera Venture Capital
Finnvera Venture Capital investment in Series A - Aurealis Pharma
Business Finland
Business Finland investment in Series A - Aurealis Pharma
Official Site Inspections
http://www.aurealispharma.com
- Host name: 206.189.123.63
- IP address: 206.189.123.63
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "Aurealis Pharma"
Aurealis Pharma Company Profile - Office Locations, Competitors …
Aurealis Pharma has 5 employees across 2 locations and $5.71 m in total funding,. See insights on Aurealis Pharma including office locations, competitors, revenue, financials, executives, …See details»
About - Aurealis Therapeutics
Previously, CEO and co-founder of Aurealis Pharma AG 2013-2020. Prior to that, CEO of Charles River Discovery Services Finland 2009-2012; CEO and co-founder of Cerebricon Ltd 2001 …See details»
Aurealis Therapeutics | Multi-target cell and gene …
Aurealis 4-in-1 multi-target cell and gene therapy platform is the game-changing solution for complex multi-factorial diseases. Discover how our technology is re-defining the treatment of chronic wounds (diabetic foot ulcers, venous leg …See details»
Aurealis Pharma - Products, Competitors, Financials, Employees ...
Aurealis Pharma AG, on the other hand, will focus on oncology with its renewed strategy and plan.” said Dr. Juha Yrjänheikki, CEO of Aurealis Therapeutics AG. (Press release) Feb 11, …See details»
Aurealis Pharma - VentureRadar
Aurealis Pharma is a biopharmaceutical company based in Kuopio, Finland. Thanks to advancements in modern biotechnology and our research and development in cell-based …See details»
Aurealis Therapeutics - LinkedIn
Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses ...See details»
Aurealis Therapeutics AG – Swiss Biotech
Type of organization. Private company. Year of foundation. 2018. Number of employees in Switzerland. 1-9. Key business. R&D; Core competencies. Therapeutics/vaccines (human) You may also be interested in . Calico …See details»
Aurealis Therapeutics - Crunchbase Company Profile & Funding
AUP-16: A genetically engineered Lactococcus Cremoris bacteria used for treating chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers by producing …See details»
Aurealis Pharma - Contacts, Employees, Board Members
Aurealis Pharma is a biopharmaceutical company. Start Free Trial . Chrome ExtensionSee details»
Aurealis Pharma Company Information - Funding, Investors, and …
Jan 1, 2019 Aurealis Pharma https://aurealispharma.com. Biopharmaceutical company focused on developing innovative therapies. GET THE TOP 10 COMPANIES OF THE WEEK IN …See details»
Aurealis Pharma CEO and Key Executive Team | Craft.co
Aurealis Pharma's CEO is Juha Yrjänheikki. Other executives include Colin Foster, Chairman of the Board; Thomas Wirth, CSO, Director and 4 others. See the full leadership team at Craft.See details»
Aurealis Therapeutics - Craft
Aurealis Therapeutics is a company that develops a treatment method for chronic non-healing wounds and other regenerative diseases. Its genetically modified lactic acid bacteria based …See details»
Aurealis Therapeutics and Xbiome Enter into a License and …
Jan 28, 2022 BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 28, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing …See details»
Aurealis Pharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Feb 12, 2019: ... Series A - …See details»
Aurealis Pharma announces funding and spin-off
Feb 11, 2019 A new company with 7.8 million Swiss francs ($7.8 million) in funding has been created to take forward an asset from private biopharma Aurealis Pharma. The spin-off is …See details»
Aurealis Pharma announces 7.8MCHF financing to advance …
Feb 11, 2019 Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF …See details»
Aurealis Therapeutics - PitchBook
Aurealis Therapeutics General Information Description. Developer of a cell and gene therapy platform designed to heal multifactorial diseases. The company's platform facilitates a novel …See details»
Aurealis Therapeutics: USD 10 million raised for multi-factor …
Mar 30, 2023 Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a …See details»
Aurealis Therapeutics: Phase 2 study for diabetic foot ulcer …
May 9, 2023 Aurealis Therapeutics, a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene …See details»